home / stock / ebs / ebs news


EBS News and Press, Emergent Biosolutions Inc. From 04/19/23

Stock Information

Company Name: Emergent Biosolutions Inc.
Stock Symbol: EBS
Market: NYSE
Website: emergentbiosolutions.com

Menu

EBS EBS Quote EBS Short EBS News EBS Articles EBS Message Board
Get EBS Alerts

News, Short Squeeze, Breakout and More Instantly...

EBS - Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023

GAITHERSBURG, Md., April 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, recent business developments, revenue guidance for the second q...

EBS - Emergent BioSolutions to amend credit agreement

2023-04-17 10:16:29 ET Emergent BioSolutions ( NYSE: EBS ) said on Monday it is set to amend an amended and restated credit agreement dated Feb. 14. The third amendment relates to the amendment of a waiver, as part of which the requisite lenders have agreed to extend the l...

EBS - Emergent jumps 13% as Benchmark upgrades with over 100% upside

2023-04-10 11:17:49 ET Shares of Emergent BioSolutions ( NYSE: EBS ) rose ~13% in the morning hours Monday after Benchmark upgraded the contract manufacturer to Buy from Hold with a $22 per share target to imply over 100% upside to Thursday’s close. As reasons for t...

EBS - Why Emergent BioSolutions Stock Is Soaring Today

2023-03-30 11:56:27 ET Shares of Emergent BioSolutions (NYSE: EBS) were soaring 11% higher as of 11:13 a.m. ET on Thursday. The big gain came after the Food and Drug Administration (FDA) approved the company's Narcan on Wednesday as an over-the-counter (OTC) treatment for opioid ove...

EBS - Emergent wins FDA nod for first over-the-counter opioid overdose therapy

2023-03-29 10:02:29 ET Emergent BioSolutions ( NYSE: EBS ) received FDA approval on Wednesday for Narcan, a nasal spray of opioid overdose therapy naloxone hydrochloride, for over-the-counter (OTC) nonprescription use. Narcan 4 milligram is the first FDA-approved naloxone ...

EBS - U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions' NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment

NARCAN ® Naloxone HCl Nasal Spray 4 mg is currently the first and only prescription strength naloxone nasal spray to receive over-the-counter status in the U.S., which is a critical step toward broadening access Expected over-the-counter availability is anticipated by late summer of ...

EBS - RIOT, MARA and HUT are among pre market gainers

2023-03-29 08:22:10 ET Arcturus Therapeutics Holdings  ( ARCT ) +28% Q4 earnings call release Lululemon Athletica  ( LULU ) +17% Q4 earnings call release Jiayin Group ( JFIN ) +15% Q4 earnings call release N-able ( NABL ) +13% jumps ...

EBS - Catalyst watch: Eyes on Deutsche Bank, Intel, Virgin Orbit and the Fed's favorite inflation gauge

2023-03-24 15:00:32 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...

EBS - Enzo, PaxMedica top healthcare gainers; Lifecore, Acer lead losers' pack

2023-03-17 10:02:41 ET Gainers: Enzo Biochem ( ENZ ) +77% . PaxMedica ( PXMD ) +22% . Nuwellis (NUWE ) +18% . Lucy Scientific Discovery ( LSDI ) +12% . Assure Holdings ( IONM ) +8% . Losers: Lifecore Biomedical (...

EBS - Sarepta Therapeutics, Credit Suisse, First Republic Bank among premarket losers' pack

2023-03-17 08:33:13 ET Diebold Nixdorf DBD -28% on liquidity concerns . Sarepta Therapeutics SRPT -18% on FDA advisory meeting for its muscular dystrophy treatment . ThermoGenesis ( THMO ) -19% . First Republic Bank FRC -15% after suspending d...

Previous 10 Next 10